Sun Pharmaceutical Industries Limited has announced that all resolutions proposed at its 34th Annual General Meeting (AGM) were passed by shareholders with the requisite majority. The meeting, held on July 31, 2026, concluded successfully, with the independent Scrutinizer submitting his final report to the company confirming the outcome. This approval validates the corporate actions and strategic decisions outlined in the notice of the AGM dated July 06, 2026.

The resolutions are now effective in accordance with the applicable provisions of law. The company has submitted the official voting results to the relevant exchanges and stakeholders. The detailed Scrutinizer Report is accessible to investors and shareholders on the company’s website at www.sunpharma.com . This process ensures transparency and compliance with regulatory requirements governing general meetings.

Key Details of the 34th AGM

The following table summarizes the key procedural details of the recent annual general meeting:

Regulatory Compliance and Reporting

Anoop Deshpande, Company Secretary and Compliance Officer of Sun Pharmaceutical Industries Limited, certified the results. The submission confirms that the voting process adhered to statutory guidelines. Shareholders are advised to refer to the company’s website for the complete Scrutinizer Report and voting breakdown. No further action is required from shareholders regarding these specific resolutions.

Sun Pharmaceutical concluded its Board of Directors meeting on July 31, 2026, marking the completion of a procedural session that began earlier in the day. The meeting, held at the company’s registered office in Mumbai, commenced at 10:50 A.M. and was adjourned for a break before resuming and concluding at 3:40 P.M. This update follows an earlier communication issued by the company regarding the scheduled convening of the board session.

The filing serves primarily as a notice of conclusion rather than a disclosure of material decisions. Sun Pharmaceutical Industries Limited did not announce any specific resolutions, financial results, or strategic approvals in this immediate communication. Investors and stakeholders are advised to monitor subsequent filings for details on any actions taken during the meeting, such as dividend declarations, capital allocation plans, or governance changes.

Meeting Details

The Company Secretary and Compliance Officer, Anoop Anjanikumar Deshpande, signed the confirmation of the meeting’s conclusion. His ICSI Membership No. is A23983. The document was digitally signed on July 31, 2026, at 18:13:45 IST.

As no material information was disclosed in this specific filing, there are no immediate implications for share price movement or operational strategy based solely on this announcement. The market will await further disclosures from the company to understand the outcomes of the deliberations held during the three-hour-plus session.